Bruce M. Dixon v. Partida, et al.

CourtDistrict Court, N.D. California
DecidedNovember 10, 2025
Docket3:22-cv-04461
StatusUnknown

This text of Bruce M. Dixon v. Partida, et al. (Bruce M. Dixon v. Partida, et al.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bruce M. Dixon v. Partida, et al., (N.D. Cal. 2025).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 BRUCE M. DIXON, Case No. 22-cv-04461-AMO

8 Plaintiff, ORDER GRANTING IN PART AND 9 v. DENYING IN PART DEFENDANTS’ MOTION FOR SUMMARY 10 PARTIDA, et al., JUDGMENT 11 Defendants. Re: Dkt. Nos. 115, 122

12 13 In this Section 1983 case, Bruce Dixon, a prisoner in the custody of the California 14 Department of Corrections and Rehabilitation (“CDCR”), brings claims of deliberate indifference 15 and equal protection violations against CDCR officials and medical providers. Defendants’ 16 motion for summary judgment was heard before this Court on October 2, 2025. Having read the 17 papers filed by the parties and carefully considered their arguments therein and those made at the 18 hearing, as well as the relevant legal authority, the Court hereby GRANTS in part and DENIES 19 in part Defendants’ motion for the following reasons. 20 I. BACKGROUND 21 A. Factual Background 22 Dixon has been under the care of CDCR for over 25 years. While incarcerated, Dixon has 23 struggled with serious mental health challenges and has been diagnosed with several mental health 24 conditions.1 Virani Decl., Ex. 1 at AGO 00010-19. At least as early as 2016, Dixon has been 25 26 1 Dixon filed an administrative motion to file under seal portions of his Opposition brief and 27 supporting exhibits. See Dkt. No. 122. Dixon seeks to seal certain portions of the record that 1 prescribed the antipsychotic medication Clozapine (trade name Clozaril).2 Virani Decl., Ex. 2 at 2 AGO 44518. 3 1. Clozaril Background 4 Clozaril is a powerful medication used to treat severe mental illness, but its use is 5 associated with serious potential side effects, including vulnerability to infection, low blood 6 pressure, slow heart rate, loss of consciousness, seizures, inflammation or enlargement of the 7 heart, drowsiness, dizziness, headaches, tremors, visual disturbances, nausea, and fever. Because 8 of the complex nature of Clozaril treatment, CDCR policy requires prisoners on Clozaril to be 9 housed at specific institutions that are qualified to administer and monitor patients on Clozaril. 10 Virani Decl., Ex. 3 at AGO 79262. These institutions are designated within CDCR as Clozapine 11 (Clozaril) maintenance facilities. Id. 12 When Clozaril is administered to a patient, four different teams must work together to 13 provide adequate care: nursing, pharmacy, psychiatry, and laboratory. Virani Decl., Ex. 4 at AGO 14 79541; Ex. 5 (“Crayton Dep.”) at 159:1-160:9. Nurses are particularly important in the 15 administration of Clozaril because they regularly conduct patient assessments, which involve 16 recording vital signs and checking for bowel function and hypersalivation. See Crayton Dep. at 17 40:21-25. CDCR policy requires that Clozaril maintenance facilities provide continuous 18 monitoring and must comply with the Clozaril Risk Evaluation and Mitigation Strategy (“REMS”) 19 program, an FDA-mandated program which ensures that facilities can maintain an adequate and 20 stable supply of Clozaril. Virani Decl., Ex. 3 at AGO 79261-63. To safely house an inmate on 21 Clozaril, it is necessary to have a stable supply of Clozaril. Clark Dep. at 79:11-80:14. Clozaril is 22 not considered a difficult medication for the prison pharmacy to obtain as it has been around for 23 over 35 years and is readily available. Id. at 79:11-80:14. In the normal course of administration, 24 the pharmacist checks the patient’s labs to make sure they were drawn, that the levels were 25 normal, and then dispenses the medication. Id. at 79:11-80:14. Due to the close monitoring that is 26 necessary of a patient taking Clozaril, however, CDCR has only approved a limited number of 27 1 institutions for the maintenance of inmates with prescriptions for Clozaril. Crayton Decl. ¶ 4 2 (ECF No. 19-1). One of these institutions is the Psychiatric Inpatient Program (PIP) at Salinas 3 Valley State Prison (“SVSP”). Id. 4 2. Placement of Dixon 5 In August 2021, Dixon was transferred to SVSP-PIP. Virani Decl., Ex. 7 at AGO 76625. 6 On December 29, 2021, Dixon was transferred to SVSP’s enhanced outpatient program (“SVSP- 7 EOP”), which was not a Clozaril maintenance facility. Virani Decl., Ex. 8 at AGO 76958; 8 Crayton Dep. at 51:24-52:1 (explaining that it was “well known that [SVSP-EOP] was not a 9 [Clozaril] maintenance facility”); see e.g., Virani Decl., Ex. 9 (“Gaither Dep.”) at 40:8-16 (same). 10 CDCR employees testified that SVSP-EOP’s pharmacy and nursing staff were inadequately 11 equipped to handle Clozaril patients. Crayton Dep. at 44:7-18; Virani Decl., Ex. 10 (“Sawyer 12 Dep.”) at 77:23-79:24. Defendant Eugene Crayton, SVSP’s Chief Psychiatrist, described Dixon’s 13 transfer to SVSP-EOP as “a complete surprise,” “a mystery,” and “highly unusual and 14 unexpected.” Crayton Dep. at 51:13-16. On December 30, 2021, CDCR Chief Psychiatrist Dr. 15 Michael Golding emphasized to the medical team at SVSP-EOP that Dixon should not be taken 16 off Clozaril and must be transferred to a Clozaril maintenance facility where he could receive 17 proper care. Virani Decl., Ex. 11 at AGO 77474-75. Multiple other staff expressed similar 18 concerns, stating that Dixon’s “mental health ha[d] clearly been impacted by the transfer delays,” 19 that the lack of timely updates on his weekly labs created “increased risks of adverse outcomes for 20 continued use of this medication,” and that he should be transferred to a Clozaril maintenance 21 facility. Virani Decl., Ex. 28 at AGO 77549; Ex. 32 at AGO 77494-96; Ex. 12 at AGO 77505-07. 22 An Institution Classification Committee (“ICC”) meeting concerning Dixon took place on 23 March 24, 2022. Sinclair Decl., Ex. A. The ICC participants noted that Dixon’s psychiatrist at 24 SVSP had recommended that Dixon be transferred to an institution which specializes in Clozapine 25 treatment. Id. The participants noted, however, that Dixon was a level 4 inmate and that he had 26 enemies at all other level 4 general population institutions. Id. Because of this, he was described 27 as a “difficult to place case.” Id. Valley State Prison (“VSP”) and Mule Creek State Prison 1 Clozapine, but both prisons were designated for level 2 inmates. Id. A level 2 facility is a lower- 2 level facility, while a level 4 facility is high security. Wilson Decl., Ex. B (“Clark Dep.”) at 3 77:3:17. The ICC therefore recommended an override and that Dixon be transferred to VSP or, 4 alternatively, MCSP. Sinclair Decl., Ex. A. One of the members of this ICC was Solis. Id. 5 The recommendation of the ICC was then reviewed by Davis on April 5, 2022. Sinclair 6 Decl., Ex. A. Given Dixon’s classification as a difficult to place case, and because the ICC 7 requested an override to send a level 4 inmate to a level 2 institution, Davis requested clarification 8 on whether a conference call with the Clozapine designated facilities had taken place. Id. 9 On May 26, 2022, another ICC was held concerning Dixon. Sinclair Decl., Ex. B; 10 Mondragon Decl. ¶ 3. It was again noted that Dixon’s psychiatrist had recommended Dixon’s 11 transfer to an institution specializing in Clozapine treatment. Sinlair Decl., Ex. B. The ICC also 12 noted, again, that Dixon was a level 4 inmate with enemies at all other level 4 general population 13 institutions. Id. The ICC therefore recommended that Dixon be transferred to MCSP, which was 14 a level 2 institution. Sinclair Decl., Ex. B; Mondragon Decl. ¶ 3. Mondragon and Borla were 15 members of the May 26, 2022 ICC. Sinclair Decl., Ex. B. 16 In June 2022, the Population Management Unit (PMU) within CDCR strove to determine 17 where Dixon could be safely housed from a custody standpoint. Foss Decl. ¶ 3; Mondragon Decl. 18 ¶ 3. Because there were overlapping custody and medical issues involved in Dixon’s placement, 19 PMU contacted Foss. Foss Decl. ¶ 3.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Johnston v. City of Houston, Tex.
14 F.3d 1056 (Fifth Circuit, 1994)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Anderson v. Creighton
483 U.S. 635 (Supreme Court, 1987)
Hudson v. McMillian
503 U.S. 1 (Supreme Court, 1992)
Hope v. Pelzer
536 U.S. 730 (Supreme Court, 2002)
Brunner v. Ohio Republican Party
555 U.S. 5 (Supreme Court, 2008)
In Re Oracle Corp. Securities Litigation
627 F.3d 376 (Ninth Circuit, 2010)
Gerhart v. Lake County, Mont.
637 F.3d 1013 (Ninth Circuit, 2011)
Hunt v. City of Los Angeles
638 F.3d 703 (Ninth Circuit, 2011)
Eric Sanchez v. Duane R. Vild
891 F.2d 240 (Ninth Circuit, 1989)
John C. McGuckin v. Dr. Smith John C. Medlen, Dr.
974 F.2d 1050 (Ninth Circuit, 1992)
United States v. Ernest Bynum, Jr.
3 F.3d 769 (Fourth Circuit, 1993)
Valjeanne Currie v. Group Insurance Commission
290 F.3d 1 (First Circuit, 2002)
Toguchi v. Soon Hwang Chung
391 F.3d 1051 (Ninth Circuit, 2004)
John Snow v. E.K. McDaniel
681 F.3d 978 (Ninth Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Bruce M. Dixon v. Partida, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/bruce-m-dixon-v-partida-et-al-cand-2025.